Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

349 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structure-activity relationships of a novel class of endothelin-A receptor antagonists and discovery of potent and selective receptor antagonist, 2-(benzo[1,3]dioxol-5-yl)-6-isopropyloxy-4-(4-methoxyphenyl)-2H-chromene-3-carboxylic acid (S-1255). 1. Study on structure-activity relationships and basic structure crucial for ET(A) antagonism.
Ishizuka N, Matsumura K, Sakai K, Fujimoto M, Mihara S, Yamamori T. Ishizuka N, et al. J Med Chem. 2002 May 9;45(10):2041-55. doi: 10.1021/jm010382z. J Med Chem. 2002. PMID: 11985472
Pyrrolinone derivatives as a new class of P2X3 receptor antagonists. Part 1: Initial structure-activity relationship studies of a hit from a high throughput screening.
Tobinaga H, Kameyama T, Oohara M, Kobayashi N, Ohdan M, Ishizuka N, Kume M, Tomari M, Tanaka Y, Takahashi F, Kinoshita H, Shimada S, Shinohara S, Kai H. Tobinaga H, et al. Among authors: ishizuka n. Bioorg Med Chem Lett. 2018 Jul 15;28(13):2338-2342. doi: 10.1016/j.bmcl.2017.04.060. Epub 2017 Apr 19. Bioorg Med Chem Lett. 2018. PMID: 29805055
Discovery of S-777469: an orally available CB2 agonist as an antipruritic agent.
Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, Mitsumori S, Morioka Y, Soga M, Deguchi M, Yasui K, Arimura A. Odan M, et al. Among authors: ishizuka n. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2803-6. doi: 10.1016/j.bmcl.2012.02.072. Epub 2012 Mar 3. Bioorg Med Chem Lett. 2012. PMID: 22444677
CB 1/2 dual agonists with 3-carbamoyl 2-pyridone derivatives as antipruritics: reduction of CNS side effects by introducing polar functional groups.
Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, Mitsumori S, Morioka Y, Soga M, Deguchi M, Yasui K, Arimura A. Odan M, et al. Among authors: ishizuka n. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2894-7. doi: 10.1016/j.bmcl.2012.02.054. Epub 2012 Mar 3. Bioorg Med Chem Lett. 2012. PMID: 22437111
Discovery of S-444823, a potent CB1/CB2 dual agonist as an antipruritic agent.
Odan M, Ishizuka N, Hiramatsu Y, Inagaki M, Hashizume H, Fujii Y, Mitsumori S, Morioka Y, Soga M, Deguchi M, Yasui K, Arimura A. Odan M, et al. Among authors: ishizuka n. Bioorg Med Chem Lett. 2012 Apr 15;22(8):2898-901. doi: 10.1016/j.bmcl.2012.02.050. Epub 2012 Feb 23. Bioorg Med Chem Lett. 2012. PMID: 22421019
Evaluation of pharmacokinetics, safety, and efficacy of [211At] meta-astatobenzylguanidine ([211At] MABG) in patients with pheochromocytoma or paraganglioma (PPGL): A study protocol.
Kobayakawa M, Shiga T, Takahashi K, Sugawara S, Nomura K, Hanada K, Ishizuka N, Ito H. Kobayakawa M, et al. Among authors: ishizuka n. PLoS One. 2024 May 28;19(5):e0303623. doi: 10.1371/journal.pone.0303623. eCollection 2024. PLoS One. 2024. PMID: 38805424 Free PMC article.
Internet of things-based approach for glycemic control in people with type 2 diabetes: A randomized controlled trial.
Bouchi R, Izumi K, Ishizuka N, Uemura Y, Ohtsu H, Miyo K, Tanaka S, Satoh-Asahara N, Hara K, Odawara M, Kusunoki Y, Koyama H, Onoue T, Arima H, Tsushita K, Watada H, Kadowaki T, Ueki K. Bouchi R, et al. Among authors: ishizuka n. J Diabetes Investig. 2024 May 7. doi: 10.1111/jdi.14227. Online ahead of print. J Diabetes Investig. 2024. PMID: 38712947 Free article.
Exploratory analysis of serum HER2 extracellular domain for HER2 positive gastric cancer treated with SOX plus trastuzumab.
Wakatsuki T, Ishizuka N, Hironaka S, Minashi K, Kadowaki S, Goto M, Shoji H, Hirano H, Nakayama I, Osumi H, Ogura M, Chin K, Yamaguchi K, Takahari D. Wakatsuki T, et al. Among authors: ishizuka n. Int J Clin Oncol. 2024 Jun;29(6):801-812. doi: 10.1007/s10147-024-02509-z. Epub 2024 Apr 8. Int J Clin Oncol. 2024. PMID: 38589679 Free PMC article.
349 results